

REGENERON PHARMACEUTICALS INC  
 Form 4  
 July 10, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Sanofi

2. Issuer Name and Ticker or Trading Symbol  
 REGENERON  
 PHARMACEUTICALS INC  
 [REGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
 \_\_\_ Officer (give title below) \_\_\_ Other (specify below)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 07/08/2014

54, RUE LA BOETIE  
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_X\_ Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

PARIS, IO 75008

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |   |
| Common Stock                    | 07/08/2014                           |  | P                              | A   | \$ 9,985<br><u>(1) (2)</u>  | 309.3301<br><u>(1) (3)</u>                               | 21,262,726 I See note (4)                             |
| Common Stock                    | 07/08/2014                           |  | P                              | A   | \$ 37,790<br><u>(1) (2)</u>   | 310.3359<br><u>(1) (5)</u>                               | 21,300,516 I See note (4)                             |
| Common Stock                    | 07/08/2014                           |  | P                              | A   | \$ 42,745<br><u>(1) (2)</u>   | 311.2548<br><u>(1) (6)</u>                               | 21,343,261 I See note (4)                             |
|                                 | 07/08/2014                           |  | P                              | A   |   |  | 21,360,275 I  |

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

|              |            |   |                          |   |                                   |            |   |  |                        |
|--------------|------------|---|--------------------------|---|-----------------------------------|------------|---|--|------------------------|
| Common Stock |            |   | 17,014<br><u>(1) (2)</u> |   | \$<br>312.1152<br><u>(1) (7)</u>  |            |   |  | See note<br><u>(4)</u> |
| Common Stock | 07/08/2014 | P | 32,331<br><u>(1) (2)</u> | A | \$<br>313.0924<br><u>(1) (8)</u>  | 21,392,606 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/08/2014 | P | 8,229<br><u>(1) (2)</u>  | A | \$<br>314.4147<br><u>(1) (9)</u>  | 21,400,835 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/08/2014 | P | 4,906<br><u>(1) (2)</u>  | A | \$<br>314.8523<br><u>(1) (10)</u> | 21,405,741 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 15,565<br><u>(1) (2)</u> | A | \$<br>304.1935<br><u>(1) (11)</u> | 21,421,306 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 20,608<br><u>(1) (2)</u> | A | \$<br>305.0939<br><u>(1) (12)</u> | 21,441,914 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 6,513<br><u>(1) (2)</u>  | A | \$<br>306.1305<br><u>(1) (13)</u> | 21,448,427 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 14,532<br><u>(1) (2)</u> | A | \$<br>307.2219<br><u>(1) (14)</u> | 21,462,959 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 14,586<br><u>(1) (2)</u> | A | \$<br>308.1936<br><u>(1) (15)</u> | 21,477,545 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 26,831<br><u>(1) (2)</u> | A | \$<br>306.2766<br><u>(1) (16)</u> | 21,504,376 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 62,861<br><u>(1) (2)</u> | A | \$<br>310.1031<br><u>(1) (17)</u> | 21,567,237 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 29,829<br><u>(1) (2)</u> | A | \$<br>311.0768<br><u>(1) (18)</u> | 21,597,066 | I |  | See note<br><u>(4)</u> |
| Common Stock | 07/09/2014 | P | 3,675<br><u>(1) (2)</u>  | A | \$<br>311.9096<br><u>(1) (19)</u> | 21,600,741 | I |  | See note<br><u>(4)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control**

SEC 1474  
(9-02)



## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

- (5) Purchase prices range from \$309.75 to \$310.73 per share, inclusive.
- (6) Purchase prices range from \$310.75 to \$311.74 per share, inclusive.
- (7) Purchase prices range from \$311.75 to \$312.68 per share, inclusive.
- (8) Purchase prices range from \$312.74 to \$313.68 per share, inclusive.
- (9) Purchase prices range from \$313.77 to \$314.69 per share, inclusive.
- (10) Purchase prices range from \$314.79 to \$315.00 per share, inclusive.
- (11) Purchase prices range from \$303.60 to \$304.59 per share, inclusive.
- (12) Purchase prices range from \$304.61 to \$305.59 per share, inclusive.
- (13) Purchase prices range from \$305.60 to \$306.56 per share, inclusive.
- (14) Purchase prices range from \$306.65 to \$307.63 per share, inclusive.
- (15) Purchase prices range from \$307.65 to \$308.64 per share, inclusive.
- (16) Purchase prices range from \$308.65 to \$309.63 per share, inclusive.
- (17) Purchase prices range from \$309.65 to \$310.64 per share, inclusive.
- (18) Purchase prices range from \$310.67 to \$311.65 per share, inclusive.
- (19) Purchase prices range from \$311.67 to \$312.23 per share, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.